Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul 1;38(8):1267-1269.
doi: 10.1097/QAD.0000000000003887. Epub 2024 May 30.

Low cabotegravir trough concentrations without oral lead-in in patients with HIV-1 switching to long-acting cabotegravir and rilpivirine

Emma Rubenstein  1 , Myriam Diemer  1 , Lauriane Goldwirt  2 , Caroline Lascoux-Combe  1 , Marie-Laure Chaix  3 , Agathe Rami  1 , Diane Ponscarme  1 , Matthieu Lafaurie  1 , Blandine Denis  1 , Nathalie De Castro  1 , Julien Gras  1 , Geoffroy Liegeon  1 , Pierre-Olivier Sellier  1 , Laure Deville  4 , Sylvie Chevret  5 , Constance Delaugerre  3 , Jean-Michel Molina  1
Affiliations

Low cabotegravir trough concentrations without oral lead-in in patients with HIV-1 switching to long-acting cabotegravir and rilpivirine

Emma Rubenstein et al. AIDS. .

Abstract

In a cohort of 72 consecutive virologically-suppressed patients with HIV-1 switching to long-acting cabotegravir and rilpivirine, we observed low cabotegravir trough concentrations 1 and 3 months after the first injection, with a significant association with no oral lead-in at 1 month [odds ratio (OR) = 6.3 [95% confidence interval (CI) 1.7-29.5], P = 0.01] and three months (OR = 5.6 [95% CI 1.3-29.7], P = 0.03), and with high BMI at 1 month (OR = 1.3 [95% CI 1.1-1.6], P = 0.007).

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Spreen WR, Margolis DA, Pottage JC. Long-acting injectable antiretrovirals for HIV treatment and prevention . Curr Opin HIV AIDS 2013; 8:565–571.
    1. Margolis DA, Gonzalez-Garcia J, Stellbrink HJ, Eron JJ, Yazdanpanah Y, Podzamczer D, et al. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, noninferiority trial . Lancet 2017; 390:1499–1510.
    1. Orkin C, Arasteh K, Gorgolas Hernandez-Mora M, Pokrovsky V, Overton ET, Girard PM, et al. Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection . N Engl J Med 2020; 382:1124–1135.
    1. Swindells S, Andrade-Villanueva JF, Richmond GJ, Rizzardini G, Baumgarten A, Masia M, et al. Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression . N Engl J Med 2020; 382:1112–1123.
    1. Orkin C, Bernal Morell E, Tan DHS, Katner H, Stellbrink HJ, Belonosova E. Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study . Lancet HIV 2021; 8:e668–e678.